| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $450,312 | 7 | 100 |
Sells | $0 | 0 | 0 |
| Lee Tien-Li | Chief Executive Officer | 5 | $358,673 | 0 | $0 | $358,673 |
| Sun Nelson | Chief Financial Officer | 2 | $91,640 | 0 | $0 | $91,640 |
Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Its lead product candidate is the ARD-101, an oral gut-restricted small-molecule agonist of certain targeting bitter taste receptors expressed in the gut lumen that is in Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome, as well as in Phase II clinical trial for hyperphagia associated with acquired hypothalamic obesity resultant from treatment of craniopharyngioma, including surgery or radiation. It also developing ARD-201, which is in Phase I clinical trial for the treatment of obesity. The company was incorporated in 2017 and is based in San Diego, California.
Over the last 12 months, insiders at Aardvark Therapeutics, Inc. Common Stock have bought $450,312 and sold $0 worth of Aardvark Therapeutics, Inc. Common Stock stock.
On average, over the past 5 years, insiders at Aardvark Therapeutics, Inc. Common Stock have bought $450,312 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Lee Tien-Li (Chief Executive Officer) — $358,673. Sun Nelson (Chief Financial Officer) — $91,640.
The last purchase of 7,000 shares for transaction amount of $101,395 was made by Lee Tien-Li (Chief Executive Officer) on 2025‑12‑11.
| 2025-12-11 | Lee Tien-Li | Chief Executive Officer | 7,000 0.0348% | $14.48 | $101,395 | -19.73% | ||
| 2025-12-11 | Sun Nelson | Chief Financial Officer | 3,000 0.0148% | $14.40 | $43,200 | -19.73% | ||
| 2025-09-15 | Lee Tien-Li | Chief Executive Officer | 10,000 0.0332% | $9.66 | $96,624 | +22.86% | ||
| 2025-09-12 | Lee Tien-Li | Chief Executive Officer | 5,000 0.0146% | $8.50 | $42,516 | +41.68% | ||
| 2025-09-11 | Lee Tien-Li | Chief Executive Officer | 6,000 0.0161% | $7.82 | $46,926 | +55.78% | ||
| 2025-09-10 | Lee Tien-Li | Chief Executive Officer | 9,000 0.0245% | $7.91 | $71,213 | +51.25% | ||
| 2025-09-09 | Sun Nelson | Chief Financial Officer | 6,000 0.0166% | $8.07 | $48,440 | +52.34% | ||
| 2007-08-17 | Creamer James W III | CFO & Treasurer | 500 0.0003% | $1.90 | $950 | |||
| 2006-12-06 | Zimlich Joseph C | director | 56,550 0.0252% | $1.30 | $73,515 | |||
| 2006-05-12 | Creamer James W III | Chief Financial Officer | 300 0.0003% | $3.05 | $915 |
| Increased Positions | 49 | +132.43% | 2M | +23.22% |
| Decreased Positions | 15 | -40.54% | 917,879 | -9.7% |
| New Positions | 22 | New | 1M | New |
| Sold Out Positions | 6 | Sold Out | 512,491 | Sold Out |
| Total Postitions | 71 | +91.89% | 11M | +13.52% |